Related Experiment Videos
PD 116,152, a novel phenazine antitumor antibiotic. Discovery, fermentation, culture characterization and biological
The Journal of Antibiotics
|February 1, 1986
Abstract:
A novel phenazine antitumor antibiotic is described, produced by Streptomyces lomondensis subsp. galanosa NRRL 15738. The antibiotic is selectively active versus the bacterium Streptococcus pneumoniae (MIC less than 0.46 microgram/ml); the antitumor activity versus murine P388 leukemia is T/C 149.
Insights
A new phenazine antibiotic from Streptomyces lomondensis shows selective activity against Streptococcus pneumoniae and antitumor effects against P388 leukemia in mice.
Area of Science:
- Microbiology
- Pharmacology
- Natural Products Chemistry
Background:
- Streptomyces species are prolific producers of bioactive secondary metabolites.
- Phenazine compounds are known for their diverse biological activities, including antimicrobial and antitumor properties.
Purpose of the Study:
- To describe a novel phenazine antibiotic produced by Streptomyces lomondensis subsp. galanosa NRRL 15738.
- To evaluate the antimicrobial and antitumor activities of this new compound.
Main Methods:
- Isolation and characterization of the novel phenazine antibiotic.
- Determination of the Minimum Inhibitory Concentration (MIC) against Streptococcus pneumoniae.
- Assessment of antitumor activity using a murine P388 leukemia model.
Main Results:
- The novel antibiotic exhibited selective activity against Streptococcus pneumoniae with a Minimum Inhibitory Concentration (MIC) less than 0.46 microgram/ml.
- The antitumor activity against murine P388 leukemia was significant, with a T/C value of 149.
Conclusions:
- Streptomyces lomondensis subsp. galanosa NRRL 15738 produces a novel phenazine antibiotic with promising selective antimicrobial and antitumor properties.
- This compound warrants further investigation for potential therapeutic applications.